OTC · HCYT
H-CYTE, Inc.
Healthcare · Biotechnology
$1.00
Down-$0.01 (-0.50%)
Updated Aug 17, 2026, 9:39 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 624.98K
- P/E ratio
- —
- Dividend yield
- —
- 52-week range
- — – —
- Volume
- 325
- Avg. volume
- 1.52K
Price performance
HCYT price history
1M range · 0 trading sessions · Daily adjusted prices
HCYT does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest HCYT news
The latest Smart Investors Daily articles mentioning HCYT.
Stock researchCompany · Overview
HCYT research
Overview
Company profile and research snapshot.
Company profile
H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
